Participant flow

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma · Source last updated 2014-09-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) Doxorubicin: 50 mg/m\^2 by vein/intravenous (IV) over 15 minutes on Day 1 of 21 day cycle Prednisone: 100 mg tablets by mouth/orally (PO) once a day on Days 1-5 of 21 day cycle Zolinza (vorinostat): Phase I Starting dose of 300 mg by mouth each evening on Days 5-14 of 21 day cycle. Cyclophosphamide: 750 mg/m\^2 by vein over 1 hour on Day 1 of 21 day cycle Vincristine : 1.4 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle

   id

   FG000

   title

   Zolinza + CHOP

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Toxicity

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         14

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Recruitment Period: 04/03/09 to 12/19/12. All participants were recruited at The University of Texas (UT) MD Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice